Awarding Success MediWales Innovation Award Winners 2011 BioWales Wales, Life Science and the World BioWales Brochure 2012 Celebrating the Conference’s 10th Anniversary SUPPORTED BY THE WELSH GOVERNMENT BioWales Brochure 2012 MediWales Review Spring 2012
Welsh Government Life Science Sector Panel Chairman’s Foreword. Life Science: At the Heart of Welsh Government. Conference Programme. Speaker Profiles. Exhibitor Profiles. Exhibitor Floor Plan. MediWales Innovation Awards.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Awarding SuccessMediWales Innovation Award Winners 2011
M E D I W A L E S M A G A Z I N E S P R I N G 2 0 1 1
BioWalesWa l e s , L i f e S c i e n c e a n d t h e Wo r l d
BioWales Brochure 2012Celebrating the Conference’s 10th Anniversary
S U P P O R T E D B Y T H E W E L S H G O V E R N M E N T
BioW
ales Brochure 2012
MediW
ales Review
Spring 2012
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
MediWales’ Spring edition of The Review encompasses the official brochure for Welsh Government’s BioWales conference 2012.
Inside you will find all the resources you need: editorial outlining Wales’ strengths and Welsh Government’s plans for this burgeoning sector; the conference programme; speaker profiles; the exhibitor directory; and a detailed floor plan.
This edition also showcases the winners of MediWales’ Innovation Awards 2011 - some of the most innovative indigenous companies and NHS personnel in Wales.
BioWales 13-14 March 2012: Innovation, Translation, Commercialisation Wales Millennium Centre, Cardiff Bay
BioWales is one of the UK’s largest life science conferences and brokerage events held outside of London. Celebrating its 10th year, the conference has moved to the iconic Wales Millennium Centre to pay homage to its success.
The two-day event will see the following keynote speakers command the stage: Professor Sir Christopher Evans, Chairman of the Welsh Government’s Life Science Sector Panel; Professor Sir Richard Sykes, Former Chairman of GlaxoSmithKline; and Professor Trevor Jones, Former Director General, ABPI.
A brokerage event with pre-arranged, one-to-one meetings will occur throughout BioWales to discuss potential collaboration projects.
On the night of 13th, BioWales’ gala dinner will host the Medilink UK Health Technology Awards to celebrate the success of life science companies throughout the UK.
MediWales Innovation Awards 2011Growing exponentially for the past six years, MediWales’ Innovation Awards has become a landmark in the Welsh life science calendar. On 8th December 2011, 250 guests, including Rt. Hon Carwyn Jones AM, First Minister of Wales and Professor Sir Christopher Evans, Chairman of the Welsh Life Science Sector Panel, came together to celebrate the achievements of 2011. During the fantastic evening at Cardiff’s Hilton Hotel, nine awards were presented: six for industry and three for NHS personnel.
Welsh Life ScienceComprising circa 300 companies, this sector brings in over £1.3 billion for the Welsh economy. With a strong medical technology cluster, Wales is aspiring to grow its biotechnology sector, seek more inward investment, and progress further into global healthcare markets.
Who are we?MediWales Part-funded by the Welsh Government, MediWales is the industry-owned forum for Wales, established to service the life science sector.
MediWales works with academics, businesses, clinicians (ABC) and business support organisations to facilitate their collaboration, improve healthcare systems in Wales, and to advise government on industry led strategy. MediWales can assist international contacts in sourcing commercial and collaborative research and development partners in Wales, helping our members to build relationships both at home and abroad.
Welcome to BioWales
Behind everygreat pint there’s a brilliant littleyeast analyser...
Our Services:
Electronics
Industrial Design
Mechanical Engineering
Software Design
Rapid Prototyping
Optronics
Value Engineering
Specialist Areas
Regulatory Support
It’s what we do. As one of the UK’s leading technology and innovation companies we take a multidisciplinary and holistic approach to turn brilliant ideas into commercial realities.
We’re fascinated by the challenges presented by imaginative clients and can offer a complete skill set for product development. This includes electronic hardware and software design, industrial and mechanical engineering plus specialist areas such as optronics and microfluidics.
We combine these capabilities with creativity, experience and absolute problem solving intelligence to deliver solutions that are innovative, commercial and practical.
Whether it’s an analyser to improve consistency in beer production or any other type of scientific instrumentation or medical product, we make it possible.
Visit us on the GX Group stand to talk to a member of our team.
Do you have a brilliant idea and need some help turning it
into a commercial reality? Maybe you need some design and
engineering flair to bring a product to a new market?
We’ve developed a pint-sized yeast analyser to help brewers achieve improved consistency and reduced costs
Make it possible
The Mayfield | Usk | Monmouthshire | NP15 1SY | UK
The MediWales Review is designed by Teamworks Design & Marketing
MediWales is a founding member of Medilink UK, the network of regional medical technology organisations that represents the interests of around 3000 organisations across the UK.
ContentsWelsh Government 4-5 Life Science Sector Panel Chairman’s Foreword
Life Science: 6-13 At the Heart of Welsh Government
Conference Programme 14-15
Speaker Profiles 18-22
Exhibitor Profiles 24-34
Exhibitor Floor Plan 35
MediWales Innovation 36-38 Awards 2011
The Welsh Government is a democratically elected body established in May 1999. With devolved powers, it is responsible for developing and implementing policies in Wales on a broad range of economic issues, including economic development, education, the environment, agriculture, housing, roads and transport.
S U P P O R T E D B Y T H E W E L S H G O V E R N M E N T
Scan here to view MediWales’ publications
W A L E S m e d i c a s p e c i a lS P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
4 5
The life sciences sector here in Wales has some good businesses, exciting academic projects and many smart and committed people. But we have the potential to achieve much more. We must capitalise on the excellent basic and translational research taking place in all of our universities. We must also raise international awareness of the quality of the Welsh life sciences brand if we are to realise some of the tremendous benefits that are possible for health and wealth in Wales.
Throughout the conference, we will hear success stories from internationally renowned business people - those who have been there, seen it and done it many times over. This is a golden opportunity for entrepreneurs and enterprising
Yn y Sector Gwyddorau Bywyd yma yng Nghymru mae rhai busnesau da, prosiectau academaidd cyffrous a llawer o bobl ddeallus ac ymroddgar. Ond mae potensial i ni gyflawni llawer mwy. Mae’n rhaid i ni fanteisio ar yr ymchwil sylfaenol a throsglwyddo sy’n digwydd yn ein prifysgolion a chodi ymwybyddiaeth yn rhyngwladol am safon brand Gwyddorau Bywyd Cymru os ydym am wireddu’r manteision aruthrol posibl i iechyd a chyfoeth Cymru.
Yn y gynhadledd byddwn yn clywed hanesion llwyddiant gan bobl fusnes sy’n cael eu cydnabod ledled y byd – y rheini sydd wedi profi llwyddiant drosodd a thro. Mae hwn yn gyfle euraidd i entrepreneuriaid a gwyddonwyr mentrus yng Nghymru i fabwysiadu syniadau
scientists in Wales to take inspirational ideas, and use them in companies and universities to take our life sciences businesses into the big leagues.
Developing the Welsh Ecosystem
The most successful life sciences clusters, such as those in the US and Cambridge, have very dense networks. We need to build an ecosystem in Wales, which is similarly vibrant and dynamic, bringing people, ideas and money together to generate serial entrepreneurship and an attractive environment for investors.
We need a focal point or local hub for the sector in Wales which is easily accessible to potential investors, partners and customers and which establishes a genuinely world class place
ysbrydoledig a’u defnyddio mewn cwmnïau a phrifysgolion i fynd â’n busnesau gwyddorau bywyd i’r lefel nesaf.
Datblygu Ecosystem Cymru
Mae gan y clystyrau Gwyddorau Bywyd mwyaf llwyddiannus, fel y rheini yn UDA a Chaergrawnt, rwydweithiau dwys iawn. Mae angen i ni feithrin ecosystem yng Nghymru sydd yr un mor gyffrous a deinamig, gan dynnu pobl, syniadau ac arian ynghyd i greu entrepreneuriaeth gyfresol ac amgylchedd deniadol i fuddsoddwyr.
Mae angen ffocws neu ganolfan leol i’r sector yng Nghymru sy’n hygyrch i fuddsoddwyr, partneriaid a chwsmeriaid, ac sy’n creu lle o safon
to connect research, development and commercialisation for all the key players and stakeholders in the sector. We want business, government, the NHS and universities to thoroughly understand what each other is doing and to interact all of the time, at every level.
We need to ensure that the life science industry here in Wales has access to appropriate funds and to meet this need, we are working closely with the Welsh Government to create a dedicated life science fund for Wales.
By delivering our strategy with your help, we can all make this vision a reality and make Wales an exciting country for exploiting life sciences and a destination of choice for business growth and inward investors the world over.
fyd-eang ar gyfer cysylltu ymchwil, datblygu a masnacheiddio i’r holl gyrff a rhanddeiliaid allweddol yn y sector. Rydyn ni am i fusnes, llywodraeth, y GIG a phrifysgolion ddeall yr hyn y mae pawb arall yn ei wneud a rhyngweithio’n gyson ar bob lefel.
Mae angen i ni sicrhau bod y diwydiant gwyddorau bywyd yma yng Nghymru yn cael digon o arian, ac i’r perwyl hwn rydyn ni’n gweithio’n agos gyda Llywodraeth Cymru i greu cronfa benodedig ar gyfer y gwyddorau bywyd yng Nghymru.
Drwy gyflwyno’r strategaeth hon gyda’ch cymorth chi, gallwn ni wireddu’r weledigaeth hon a gwneud Cymru’n wlad gyffrous ar gyfer y gwyddorau bywyd ac yn lle i fusnesau a buddsoddwyr o bedwar ban ddod i dyfu.
‘Making it Happen’: A New Vision for the Welsh Life Sciences Sector
‘Gwneud i Bethau Ddigwydd’: Gweledigaeth Newydd ar gyfer Sector Gwyddorau Bywyd Cymru
The tenth anniversary of BioWales 2012 provides the perfect showcase for myself, as Chair of the Welsh Government’s Life Sciences Panel, to unveil our vision for a new strategy for the sector in Wales.
Mae deg mlwyddiant BioCymru 2012 yn gyfle perffaith i fi, fel Cadeirydd Panel Gwyddorau Bywyd Llywodraeth Cymru, ddatgelu’n gweledigaeth ar gyfer strategaeth newydd i’r sector yng Nghymru.
The delivery plan starts now! At BioWales 2012 we kick off the ecosystem that Wales needs to begin to realise the potential of the sector as a whole.
Mae’r cynllun cyflawni yn dechrau nawr! Yn BioCymru 2012 rydyn ni’n dechrau creu’r ecosystem y mae ei angen ar Gymru i ddechrau gwireddu potensial y sector cyfan.
Professor Sir Chris Evans OBEYr Athro Syr Chris Evans OBE
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
Why Life Science?
A fast growing sector, currently three of Wales’ ten most profitable companies operate in life sciences. Comprising over 300 companies, this priority sector has expertise in many areas including medical devices, in vitro diagnostics, e-health and wound care.
Many Welsh companies are operating globally developing innovative new treatments and products, including: GE Healthcare (medical imaging,
medical diagnostics, patient monitoring systems, disease research, drug discovery), Ortho Clinical Diagnostics (diagnostic, screening products and transfusion medicine), Penn Pharma (pharmaceuticals), and ConvaTec (wound healing and manufacturing).
With healthcare markets in BRIC countries expanding exponentially year-on-year, helping companies access these foreign markets is a priority. Welsh Government’s Life Sciences Panel is working to ensure Wales’ infrastructure nurtures industry success.
Meet the Panel
Our Life Science Panel members are industry experts with the expertise to promote Wales globally. The panel has developed an exciting new strategy, which the Life Sciences Team will be delivering from April 2012, including a comprehensive suite of trade support activities.
The Welsh Government Life Sciences Team – Supporting Business Growth
The Life Sciences Team can offer access to appropriate networks, employee development opportunities, NHS procurement advice, trade and export development, R&D, funding advice, and property opportunities for both existing Welsh businesses and potential inward investors.
6
Academic Excellence
Our colleges and universities have excellent knowledge transfer and commercialisation capabilities offering attractive partnering opportunities for life science businesses. Academics are housed in facilities such as the Institute of Life Science at Swansea University - a £30 million building featuring high-tech clinical research facilities and an imaging suite - a fantastic location for high-growth businesses.
Research Excellence in Wales
Cardiff University Welsh Anaesthetic Institute (WAI) – The Institute exemplifies the strong relationship between the NHS and our universities. The Institute houses senior academics and consultant
anaesthetists who develop patents, evaluate medical equipment and conduct clinical trials.
Wound Healing Research Unit (WHRU) – A leading research centre in wound care, the Unit provides specialist clinical services, research, and training, including clinical trials.
Swansea Universitye-Health Industries Innovation Centre (ehi²) – As the global e-Health market continues to grow, ehi² provides the ideal environment for businesses to access clinical, software and systems development, NHS data, clinical trials and evaluation expertise.
The Centre for NanoHealth – Based on the application of nanotechnology-leading innovations in healthcare, this interdisciplinary centre gives access
to patients, allowing for the design, manufacture, testing and evaluation of novel devices and sensors.
Supporting Business Success
The Welsh Government supports companies influencing science with innovative techniques; organisations with the expertise to take research from ‘bench to bedside’; and universities with excellent knowledge transfer track records.
Innovation
Ground-breaking technology is being developed by:
Calon Cardio – Their implantable pumps that treat heart failure are cheaper than current models available and require less invasive surgery to fit.
Microvisk – Their pioneering devices monitor blood clotting levels for patients taking drugs such as Warfarin.
Diurnal – Their novel physiological approaches to drug delivery will help patients suffering from reduced cortisol and testosterone levels.
Translation
Welsh companies taking research from bench to bedside include:
Cellnovo – developed the first mobile diabetes management system.
Life Science – At the Heart of Welsh GovernmentFor BioWales’ 10th Anniversary, the Welsh Government is unveiling its ambitious sector strategy and is introducing the best in Wales to the best in the world.
The international focus of this year’s event reflects the Welsh Government’s commitment to help businesses capture a share of global markets. We are showcasing a diverse range of industry players, whilst demonstrating why Wales is a prime destination for investors. Panel members from left to right: Dr Graham Guildford, Professor Sir Chris Evans,
Dr Penny Owen, Professor Gareth Morgan, Gwyn Tudor. Professor Chris McGuigan is also a panel member.
6 7
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
Huntleigh Diagnostics – developed a medical device which detects the early onset of lower limb arterial disease.
Magstim – developed non-invasive neurostimulation and monitoring products based on technology used by hospitals and researchers worldwide.
BioMonde – manufactures larval therapy products for the global wound care market.
Commercialisation
Companies taking Welsh technology to global markets include:
Inhibitex – this Cardiff University spin-out successfully developed a drug to treat Hepatitis C and was recently sold to American pharmaceutical giant Bristol-Myers in a $2.5 billion (£1.6 billion) deal.
Q Chip – produce innovative sustained-release drug formulations for cancer and other diseases.
Haemair, DTR Medical, Haemaflow and Swansea University’s College of Engineering and Industry – a two-year project to develop respiratory aids which mimic the performance of healthy lungs.
Applied Enzyme Technology – develop protein stabilisation tools for the pharmaceutical and environmental industries.
Recent Funds Raised Include:Cellnovo £30 million
Microvisk £10.5 million
Q Chip £8.5 million
Diurnal £1 million
Acuitas Medical £1 million +
Calon Cardio £2.2 million
Only Men Aloud – Gala Dinner Performance
Only Men Aloud will be performing their eclectic repertoire at the BioWales 10th anniversary gala dinner, putting a fresh spin on the Welsh male choir tradition.
The choir won the BBC’s Last Choir Standing programme in the summer of 2008, and released their debut album shortly afterwards, which went gold in the UK. Their second album ‘Band of Brothers’ went straight to the top of the classical charts, and they completed two sell out tours of the UK in 2009.
Only Men Aloud exemplify what this year’s conference is all about – showcasing the best of Wales to the world and succeeding in style.
Why Wales?In Wales we know what inward investors need, and the commercial pressures you face – we’ve been helping companies locate here for decades.
People and training - A skilled workforce is a vital company asset. With a track record of academic-industrial collaboration, Welsh graduates have the skills to join your company. Good quality companies and universities keep graduates in Wales – explaining why our staff retention is higher than the UK average into the potential labour market.
Property - Wales has an exceptional variety of business property – from serviced offices to international headquarters; starter industrial units to R&D incubators - and we even have property with runway access or dedicated airspace.
Access to funding - We encourage business growth by identifying sources of support and funding in areas such as skills development, academic collaboration and business expansion.
To find out more about life science business in Wales, join us at Stand 38 or contact us: tel: 03000 6 0 3000 email: [email protected]
* Primer digestion data was obtained by scientists at GE Healthcare, using experimental conditions as set out in the manufacturers operating instructions for USB ExoSAP-IT.
The new illustra ExoStar PCR and Sequence Reaction Clean-Up Kit updates existing enzymatic PCR clean up technology with new illustra Exonuclease I and Alkaline Phosphatase to remove unincorporated primers and dNTPs more efficiently than USB® ExoSAP-IT®. illustra ExoStar improves digestion efficiency with no degradation of the target PCR product as compared with USB ExoSAP-IT. Your sample is completely intact and ready for immediate use in manual or automated processes. You’d think this innovation would cost more, yet it actually costs less. illustra ExoStar. The last word on PCR cleanup from the scientists who developed it first.
For a free sample, visit www.gelifesciences.com/illustraExoStar today.
Introducing more efficient PCR purification with illustra™ ExoStar™.
10 pmol of 5’-FAM labeled 20mer digested according to manufacturer’s instruction. No detectable primer remained in samples digested with illustra ExoStar, but undigested primer remained in samples treated with USB ExoSAP-IT*
Undigested primer
illustra™ ExoStar™
Digested dinucleotide
USB®
ExoSAP-IT®
9
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
10 11
Pam Gwyddorau Bywyd?
Mae’r sector yn tyfu’n gyflym, gyda thri o’r deg cwmni mwyaf proffidiol yng Nghymru ar hyn o bryd yn gweithio yng ngwyddorau bywyd. Mae dros 300 o gwmnïau yn y sector blaenoriaeth hwn, sydd ag arbenigedd mewn sawl maes fel dyfeisiadau meddygol, diagnosteg in vitro, e-iechyd a gofal clwyfau.
Mae llawer o gwmnïau Cymru yn gweithredu’n fyd-eang i ddatblygu triniaethau a chynhyrchion arloesol, gan gynnwys: GE Healthcare (delweddu
meddygol, diagnosteg meddygol, systemau monitro cleifion, ymchwil clefydau, canfod cyffuriau), Ortho Clinical Diagnostics (diagnosteg, cynhyrchion sgrinio a meddygaeth trallwyso), Penn Pharma (fferylliaeth), a ConvaTec (gwella clwyfau a gweithgynhyrchu).
Gyda marchnadoedd gofal iechyd Brasil, Rwsia, India a Tsieina yn ehangu bob blwyddyn, mae’n rhaid blaenoriaethu helpu cwmnïau i fanteisio ar y marchnadoedd tramor hyn. Mae Panel Gwyddorau Bywyd Llywodraeth Cymru yn gweithio i sicrhau bod seilwaith Cymru yn meithrin llwyddiant yn y diwydiant.
Cwrdd â’r Panel
Mae aelodau’n Panel Gwyddorau Bywyd yn arbenigwyr yn y diwydiant gyda’r arbenigedd i hyrwyddo Cymru’n fyd-eang. Mae’r panel wedi datblygu strategaeth gyffrous newydd y bydd y Tîm Gwyddorau Bywyd yn ei chyflwyno o fis Ebrill 2012 ymlaen, gan gynnwys cyfres gynhwysfawr o weithgareddau cymorth masnach.
Tîm Gwyddorau Bywyd Llywodraeth Cymru – Cefnogi Twf Busnes
Gall y Tîm Gwyddorau Bywyd gynnig mynediad i rwydweithiau priodol, cyfleoedd datblygu staff, cyngor caffael y GIG, datblygu masnach ac allforio, ymchwil a datblygu, cyngor cyllid, a chyfleoedd eiddo ar gyfer busnesau presennol Cymru a buddsoddwyr posibl o’r tu allan.
Rhagoriaeth Academaidd
Mae gan ein colegau a’n prifysgolion adnoddau trosglwyddo gwybodaeth a masnacheiddio rhagorol sy’n cynnig cyfleoedd partneru da i fusnesau gwyddorau bywyd. Mae ysgolheigion yn gweithio mewn cyfleusterau fel yr Athrofa Gwyddor Bywyd ym Mhrifysgol Abertawe, adeilad gwerth £30 miliwn gyda chyfleusterau clinigol technoleg uwch ac ystafell ddelweddu, sy’n lleoliad gwych i fusnesau twf uchel.
Rhagoriaeth Ymchwil yng Nghymru
Prifysgol Caerdydd
Ysgol Anestheteg Cymru (WAI) – Mae’r Ysgol yn enghraifft o’r berthynas gref rhwng y GIG a’n prifysgolion.
Mae ysgolheigion profiadol ac anesthetegwyr ymgynghorol yn gweithio yn yr Athrofa, gan ddatblygu patentau, gwerthuso offer meddygol a chynnal treialon clinigol.
Yr Uned Ymchwil Gwella Clwyfau (WHRU) – Fel canolfan ymchwil flaenllaw mewn gofal clwyfau, mae’r Uned yn cynnig gwasanaethau, ymchwil a hyfforddiant clinigol arbenigol, gan gynnwys treialon clinigol.
Prifysgol Abertawe
Canolfan Arloesi’r Diwydiannau e-Iechyd (ehi²) – Wrth i’r farchnad e-iechyd fyd-eang barhau i dyfu, mae ehi² yn cynnig yr amgylchedd delfrydol i fusnesau gael arbenigedd ar ddatblygu clinigol, meddalwedd a systemau, data’r GIG, treialon clinigol a gwerthuso.
Y Ganolfan NanoIechyd – Mae’r ganolfan ryng-ddisgyblaeth hon yn gweithio i gymhwyso arloesiadau nanotechnoleg mewn gofal iechyd a rhoi mynediad i gleifion, gan ganiatáu cynllunio, gweithgynhyrchu, profi a gwerthuso dyfeisiadau a synwyryddion newydd.
Cefnogi Llwyddiant Busnes
Mae Llywodraeth Cymru yn cefnogi cwmnïau sy’n dylanwadu ar wyddoniaeth gyda thechnegau arloesol, cyrff â’r arbenigedd i fynd ag ymchwil ‘o’r labordy i’r ysbyty’, a phrifysgolion â chefndir rhagorol o drosglwyddo gwybodaeth.
Arloesi
Mae technoleg arloesol yn cael ei datblygu gan:
Calon Cardio – mae pympiau mewnblanadwy’r cwmni hwn i drin methiant y galon yn rhatach na’r modelau sydd ar gael ar hyn o bryd ac mae’r driniaeth i’w gosod yn haws.
Microvisk – mae dyfeisiau arloesol y cwmni hwn yn monitro lefelau ceulo’r gwaed mewn cleifion sy’n cymryd cyffuriau fel Warfarin.
Diurnal – bydd dulliau ffisiolegol newydd y cwmni hwn ar gyfer rhoi cyffuriau yn helpu cleifion sy’n dioddef o lefelau cortisol a testosteron isel.
Trosglwyddo
Mae’r cwmnïau yng Nghymru sy’n mynd ag ymchwil o’r labordy i’r ysbyty yn cynnwys:
Cellnovo – wedi datblygu’r system symudol gyntaf ar gyfer trin diabetes.
Gwyddorau Bywyd – Yn Ganolog i Lywodraeth CymruAr gyfer deng mlwyddiant BioCymru, mae Llywodraeth Cymru yn dadorchuddio’i strategaeth sector uchelgeisiol ac yn cyflwyno’r gorau o Gymru i’r gorau yn y byd.
Mae ffocws rhyngwladol y digwyddiad eleni yn adlewyrchu ymrwymiad Llywodraeth Cymru i helpu busnesau i sicrhau’u cyfran o farchnadoedd byd-eang. Rydyn ni’n arddangos amrywiaeth eang o ffigurau pwysig yn y diwydiant, gan ddangos pam bod Cymru’n farchnad ragorol i fuddsoddwyr. Aelodau’r Panel o’r chwith i’r dde: Dr Graham Guildford, yr Athro Syr Chris Evans,
Dr Penny Owen, yr Athro Gareth Morgan, Gwyn Tudor. Mae’r Athro Chris McGuigan hefyd yn aelod o’r panel.
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
The Business ChallengeMoving your healthcare projects forward
Huntleigh Diagnostics – wedi datblygu dyfais feddygol sy’n synhwyro’r arwyddion cyntaf o glefyd rhedwelïol yn y coesau.
Magstim – wedi datblygu cynhyrchion niwroysgogi a monitro heb lawdriniaeth ar sail technoleg a ddefnyddir gan ysbytai ac ymchwilwyr ledled y byd.
BioMonde – yn gweithgynhyrchu cynhyrchion therapi larfa ar gyfer y farchnad gofal clwyfau fyd-eang.
Masnacheiddio
Mae’r cwmnïau sy’n mynd â thechnoleg o Gymru i farchnadoedd byd-eang yn cynnwys:
Inhibitex – sgil-gwmni o Brifysgol Caerdydd sydd wedi llwyddo i ddatblygu cyffur i drin Hepatitis C ac a werthwyd yn ddiweddar i’r cwmni fferyllol Americanaidd anferthol Bristol-Myers mewn cytundeb $2.5 biliwn (£1.6 biliwn).
Q Chip – fformwleiddiadau cyffuriau rhyddhau cyson arloesol ar gyfer canser a chlefydau eraill.
Haemair, DTR Medical, Haemaflow a Choleg Peirianneg a Diwydiant Prifysgol Abertawe – prosiect dwy flynedd i ddatblygu cymhorthion anadlu sy’n efelychu ysgyfaint iach.
Applied Enzyme Technology – offer sefydlogi protein ar gyfer y diwydiannau fferyllol ac amgylcheddol.
Mae’r arian a godwyd yn ddiweddar yn cynnwys:Cellnovo £30 miliwn
Microvisk £10.5 miliwn
Q Chip £8.5 miliwn
Diurnal £1 miliwn
Acuitas Medical £1 miliwn +
Calon Cardio £2.2 miliwn
Only Men Aloud – Perfformiad Cinio Gala
Bydd Only Men Aloud yn perfformio’u repertoire amrywiol yng nghinio gala deng mlwyddiant BioCymru, gan roi blas newydd ar y traddodiad corau meibion.
Enillodd y côr yn rhaglen Last Choir Standing ar y BBC yn haf 2008, gan ryddhau’u halbwm cyntaf yn fuan wedi hynny, a enillodd statws aur yn y DU. Aeth eu hail albwm ‘Band of Brothers’ yn syth i frig y siartiau clasurol, a chwblhawyd dwy daith a werthodd allan yn y DU yn 2009.
Mae Only Men Aloud yn enghraifft berffaith o hanfod y gynhadledd eleni – arddangos y gorau o Gymru a llwyddo â steil.
Pam Cymru?Yng Nghymru rydyn ni’n gwybod beth sydd ei angen ar fuddsoddwyr o’r tu allan a’r pwysau masnachol sydd arnyn nhw – rydyn ni wedi bod yn helpu cwmnïau i symud yma ers degawdau.
Pobl a hyfforddiant – mae gweithlu medrus yn ased hanfodol i gwmni. Gyda chefndir o gydweithredu academaidd a diwydiannol, mae gan raddedigion o Gymru y sgiliau i ymuno â’ch cwmni. Mae cwmnïau a phrifysgolion o safon sy’n cadw graddedigion yng Nghymru, sy’n esbonio pam rydyn ni’n cadw mwy o staff na chyfartaledd y DU yn y farchnad lafur.
Eiddo – mae gan Gymru amrywiaeth eithriadol o eiddo busnes, o swyddfeydd â gwasanaeth i bencadlysoedd rhyngwladol, ac o unedau diwydiannol i ganolfannau deori ymchwil a datblygu. Mae hyd yn oed eiddo ar gael gyda llwybr glanio neu awyrofod.
Mynediad i gyllid – Rydyn ni’n annog twf busnes drwy ddod o hyf i gymorth a chyllid mewn meysydd fel datblygu sgiliau, cydweithredu academaidd ac ehangu busnes.
I gael mwy o wybodaeth am fusnesau gwyddorau bywyd yng Nghymru, dewch i’n gweld ni ar stondin 38 neu ffoniwch ni ar 03000 6 0 3000 neu e-bostiwch [email protected]
13
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
BioWales 2012 ProgrammeDay 1 – Tuesday 13th March 2012MC- Gareth Morgan, Institute of Life Science
Day 2 – Wednesday 14th March 2012MC- Sue Heatherington, Heatherington & Co
Opens Conference
Opening Address: Whither Life Sciences
A New Vision for Life Science in Wales
Welcome Address
Science for Wales: a Strategic Agenda for Science and Innovation in Wales
Current and Future Direction of the Pharmaceutical Industry and the Role of SMEs
ProTides: From Lab Science to Wall Street (and to patients)
From Cardiff and Two Employees to $2.5 Billion Dollars
Concept to Commercialisation in Life Sciences
Public Funding of Innovation in Life Sciences – Future Challenges
Innovation in Clinical Bioanalysis
Innovating Pre-Clinical Drug Development – Towards an Integrated Approach to Investigate Toxicology in Human Models
New Models for BioScience Innovation
Developing a Stem Cell Therapy for Stroke Patients – the Translational Challenge
Companion Diagnostics – a Key Component in Modern Medicine
‘What’s the Point of Care?’ – Showing Research Makes a Difference
Collaborative Working Between Industry, Higher Education Institutes and NHS Wales
Lions and Donkeys – Will Translation Improve Attrition in Pharmaceutical Research?
Rapid Recovery Knee Arthroplasty Patient Pathway – A New Service Model for Orthopaedic Care
Turning Good Science into Commercial Success – Case Histories from Biotechnology
Innovation Versus Process – the Balancing Act for Successful New Product Development in Diagnostics
Registration and Coffee
Exhibition
Professor Sir Christopher Evans, OBE
Sir Richard Sykes
Professor Sir Christopher Evans, OBE
Edwina Hart MBE OStJ AM, Minister for Business, Enterprise, Technology and Science
Professor John Harries, Chief Scientific Adviser for Wales
Professor Trevor Jones, CBE, Chairman, Association of British Pharmaceutical Industry (ABPI)
Lunch
Exhibition and Brokerage Meetings
Innovation
Professor Chris McGuigan, Professor of Medicinal Chemistry and Deputy Pro-Vice Chancellor of Research, Cardiff University
Gabriele Cerrone, Chairman and Founder, BioVitas Capital
Dr David Bott, Director of Innovation Programmes, Technology Strategy Board (TSB)
John Jeans, Chairman, Cardiff University Council, MRC Technology and Imanova
Q&A
Coffee Break and Exhibition
Ian James, Director, A4P Consulting
Dr Nick Thomas, Principal Scientist in Cell Technologies, GE Healthcare
Rowan Gardner, Chairman, BioLauncher
Q&A
Close
Exhibition
Brokerage Meetings
Gala Dinner
Drinks Reception
Dinner and Medilink UK Awards Ceremony
Close
Exhibition and Brokerage Meetings
Coffee Break
Translation
Michael Hunt, BSc ACA, CEO, ReNeuron
Berwyn Clarke, Board Director and Chief Scientific Officer, Lab21
Coffee Break and Exhibition
David Ford and Dr Steven Conlan, Institute of Life Science
Professor Jonathan Bisson, Clinical Director, NISCHR AHSC
Dr Trevor Howe, Head of Structural Biology and Biophysics, Janssen, a Johnson and Johnson company
Q&A
Lunch
Exhibition and Brokerage Meetings
Commercialisation
Mike Thompson, Managing Director, Biomet UK Healthcare Ltd
Kenneth Powell, Executive Chairman, Q Chip
Dr Pete Corish, British Biocell International (BBI)
Q&A
Coffee Break and Exhibition
Close
8:00
8:00 – 10:00
10:00
10:10
10:30
11:05
11:15
11:35
12:00 – 14:00
12:00 – 14:00
14:00
14:15
14:30
14:45
15:00
15:15
15:45
16:00
16:15
16:30
16:45
16:45 – 18:00
16:45 – 18:30
18:00
18:45
22:15
8:00 – 9.30
8:00 – 9.30
9:30
9.50
10:10
10:40
11:05
11:25
11:45
12:00 – 14:00
12:00 – 14:00
14:00
14:20
14:40
15:00
15:15
15:35
16.30
Facilitated Finance Discussion
Ifan Evans, Head of Life Science Sector, Welsh Government
Dominic Griffiths, Senior Life Science Director, Fusion IP
Dr Melanie Goward, Senior Investment Executive, Finance Wales
Brenig Preest, Investment Director, Excalibur Group Holdings Ltd
Day 1
Day 2
Sellgman Room
Sellgman Room
UKTI Workshop – How to Access the US Healthcare Market
GE Startup Workshop – Working with SMEs to deliver growth
13:15 – 13:45
13:15 – 13:45
Workshops
14 15
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
11
KnowledgeTransferNetwork
HealthTechand Medicines
Building a Healthy Nation through Business Innovation
Discover how the HealthTech and Medicines KTN can help your organisation innovate for the futureThe HealthTech and Medicines KTN supports business innovation through partnerships, funding and knowledge transfer
� Connecting partners: Bringing together and facilitating collaborations with a common goal� Access to funding: Identify and influence new and existing sources of funding� Knowledge transfer: Opening doors to wider networks of people, organisations
Potential practitioner network into industry and industry friendly academia
Technology Strategy Board, National and EU funding competitions
Impartial advice and access to the full KTN team
Key individuals within the community – putting you in touch with the right partners for forming collaborations
Networking opportunities and event
Membership of the KTN provides access to:
Potential practitioner network into industry and industry friendly academia
Technology Strategy Board, National and EU funding competitions
Impartial advice and access to the full KTN team
Key individuals within the community – putting you in touch with the right partners for forming collaborations
Networking opportunities and event
Membership of the KTN provides access to:
The HealthTech and Medicines Knowledge Transfer Network is a single front door through which members can find all the expertise and support they need across the innovation chain, from first idea, to patenting and packaging intellectual property, finding academic and industrial partners for product development and manufacturing scaleup, meeting regulatory standards, and getting access to market.
The HealthTech and Medicines KTN also help members to access funding from the Technology Strategy Board for prototype development and proof of concept work.
For more information and how to engage with the HealthTech and Medicines KTN community visit: www.innovateuk.org/healthktn
Medilink’s PR team deliver bespoke communication solutions to strategically support your organisation’s growth regionally, nationally and internationally through traditional, digital and social media channels.
TO READ MORE ABOUT OUR SERVICES VISIT: WWW.MEDILINKUK.COM
TO FIND OUT MORE AND DISCUSS YOUR REQUIREMENTS EMAIL: [email protected]
MEDILINK UK SERVICES
SECTOR LEADING SERVICES TO GIVEYOU THE COMPETITIVE ADVANTAGE
Medilink’s International team are at the forefront of the rapidly expanding global healthcare marketplace and can provide you with access to it.
INTERNATIONAL
If you’re looking for grants, funding or investment, Medilink collates opportunities in the health technology market; plus the background information you need to ensure your application is successful.
FUNDING AND FINANCE
Medilink’s PR team deliver bespoke communication solutions to strategically support your organisation’s growth regionally, nationally and internationally through traditional, digital and social media channels.
PR AND COMMUNICATIONS
Medilink understands that the most important job for your sales team is to make the sale.
Our job is to provide the tender and sales leads you need to grow your business.
TENDERS AND SALES LEADS
Each MedilinkUK membership organisation has specialist skills and expertise to give your company that extra competitive advantage in the marketplace Below is a selection of a few of our services - visit www.MedilinkUK.com to see more:
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
Speaker Profiles
MC – Professor Gareth Morgan Professor of Paediatrics and Immunology and Dean and Head of Swansea University’s College of Medicine
Professor Gareth Morgan began his career at Great Ormond Street Hospital in London, where his work involved the treatment of otherwise fatal genetic immunodeficiency disorders by stem cell transplantation. Gareth led the clinical team that performed the first gene therapy in the United Kingdom and the establishment of the UK regulatory body for gene therapy. Gareth was seconded as a Wellcome Trust Lecturer in Tropical Diseases for two years at the Medical Research Council (MRC) unit in The Gambia, West Africa.
Gareth is a Fellow of the Royal Colleges of Physicians, Pathologists and Paediatrics and Child Health. He is a member of a number of organisations including the European Society for Immunodeficiency (ESID). He is also Vice-Chair of the Welsh Government’s Life Science Sector Panel.
MorningProfessor Sir Christopher Evans, OBE
Sir Christopher’s considerable contributions to the biotechnology industry were honoured with a Knighthood in the 2001 New Year’s Honours List and an OBE in the 1995 New Year’s Honours List. In 1987-1994 he created Cambridge’s first biomedical companies, starting the now famous Cambridge Cluster which has grown from Sir Chris’ earlier start ups to some 350 companies worth over $7 billion. In 1996, Sir Chris founded Merlin Biosciences, which currently manages over €500 million and is one of Europe’s foremost venture capital firms specialising in medical sciences. Sir Chris has established forty-five successful, high-quality science companies, twenty of which have been taken public on 5 stock markets.
Sir Richard Sykes
Sir Richard is Chairman of a wide range of prestigious organisations and companies including Imperial College Healthcare NHS Trust, the Royal Institution of Great Britain, the UK Stem Cell Foundation, the Careers and Research Advisory Council (CRAC), Toumaz, Circassia, Omnicyte and NetScientific. Sir Richard sits on the investment board of Deepridge Capital and is Vice-Chairman of the Swiss life sciences company, Lonza Group. He also sits on the advisory boards of Siemens Holdings plc and the Virgin Group.
Professor Trevor Jones CBE – Chairman, Association of the British Pharmaceutical Industry (ABPI)
Professor Jones is former Director General of the Association of the British Pharmaceutical Industry (ABPI) and now serves on the boards of a wide range of companies in the USA and Europe, including Allergan Inc and VeronaPharma plc.
Professor Jones was previously a Director of The Wellcome Foundation, responsible for Research & Development. He is a founder member of the Geneva-based, Public: Private Partnership, Medicines for Malaria Venture and has served on the World Health Organisation Commission on Intellectual Property Rights, Innovation and Public Health.
Professor Jones was a member of the UK Government Regulatory Agency for twelve years. In 2005 he won the SCRIP Life Time Achievement award for his contribution to the pharmaceutical sciences and industry.
AfternoonProfessor Chris McGuigan Professor of Medicinal Chemistry and Deputy Pro-Vice Chancellor of Research, Cardiff University
Professor Chris McGuigan has received research funding of over £8 million since 1999. Three compounds discovered in his lab have now reached clinical trials.
Professor McGuigan served on the board of Inhibitex which holds the license for INX-189. This drug is mid-way through phase 2 trials for the Hepatitis C virus. Inhibitex was recently taken over by Bristol-Myers Squibb in a deal worth $2.5bn. He also serves on the board of Synergy Pharmaceuticals, a public company in the GI space. Chris is the inventor of ProTides, a novel drug discovery method for viruses and cancer and is a member of the Life Science Sector Panel of the Welsh Government. He also sits on the government-appointed REF panel assessing UK HEI research in health sciences.
Gabriele Cerrone Chairman and Founder, BioVitas Capital
Mr Cerrone is Chairman and Founder of BioVitas Capital, an international biotech incubator. BioVitas invests in early stage biotech intellectual property in Italy and has founded six biotech companies. Five of these companies have been listed and three of the five have hit values exceeding $900 million.
Mr Cerrone co-founded FermaVir Pharmaceuticals Inc. and served as its Chairman until 2007, when it was acquired by Inhibitex. He is the Chairman and Co-founder of Synergy Pharmaceuticals Inc, a Nasdaq-listed pharmaceutical company focusing on GI disorders. He is the Chairman and Founder of GenSignia Inc, a diagnostic microRNA company, which is developing a breakthrough plasma test for the early stage detection of lung cancer.
Sir Richard previously worked as a Senior Independent Director and non-executive Chairman of ENRC, Chairman of NHS London and Rector of Imperial College London. He has previously served as Chief Executive and Chairman of GlaxoWellcome and Chairman of GlaxoSmithKline. Internationally, he is Chairman of the International Advisory Board; A*Star Biomedical Research Council, Singapore; and a board member of EDBI. He received a Knighthood in the 1994 New Year’s Honours list for his services to the pharmaceutical industry.
Edwina Hart MBE OStJ AM Minister for Business, Enterprise, Technology and Science
Edwina Hart has been the Gower’s AM since the first Assembly election in 1999.
Having served as Minister for Finance and Local Government (2000-2003) and Minister for Social Justice and Regeneration (2003-2007), Edwina was appointed to the Health and Social Services portfolio in May 2007. Following re-election to the National Assembly for Wales in May 2011, Edwina Hart was appointed Minister for Business, Enterprise, Technology and Science.
Professor John Harries Chief Scientific Adviser for Wales
Professor John Harries, originally from Aberavon, took up post as the Chief Scientific Adviser for Wales on 1 May 2010. He is the University of London Professor of Earth Observation at the Blackett Laboratory of Imperial College London and a member of the Grantham Institute for Climate Research at the College. He is a past President of the Royal Meteorological Society, and of the International Radiation Commission. He was the first Director of the Space Science Department at the Rutherford Appleton Laboratory, and has been a senior adviser to the UK Government in several roles. He has been awarded the U.S. National Aeronautics and Space Administration’s (NASA) most prestigious civilian honour in recognition of his distinguished public service in advancing knowledge of the Earth’s atmosphere and climate change.
Dr David Bott Director of Innovation Programmes, Technology Strategy Board (TSB)
David began his career working at the British Petroleum Research Centre and subsequently joined Courtaulds to set up and run their Strategic Research Group. He has worked for ICI Acrylics as Research Director and National Starch, where he was responsible for research in their Specialty Synthetic Resins Division for 2 years.
David previously held the role of Director of Group Technology at ICI and sat on the UK Government’s Technology Foresight Panel for Materials. He was President of the Industrial Affairs Division of the Royal Society of Chemistry and served as Co-Chairman of the Strategy and Implementation Board of the Crystal Faraday Partnership on Green Chemistry. He is Chairman of Oxford Biomaterials and a Non-Executive Director of Oxford Advanced Surfaces Group, Apaclara and Spineless Design.
John Jeans Chairman, Cardiff University Council, MRC Technology and Imanova Ltd
In addition to John’s Chairmanships, he is a Non-Executive Director of the Alliance Medical Group and a Trustee of the Francis Crick Institute. Previously, John was the Deputy Chief Executive and Chief Operating Officer of the MRC, the UK’s largest funding agency for Medical Research.
John has worked with numerous companies including Smith & Nephew and Johnson & Johnson. He led the commercial function of GE’s life science business and was the Chairman of its UK healthcare operations. John has held executive posts in organisations such as the British In Vitro Diagnostic Association (BIVDA).
John is Chair of the TSB’s Rapid Diagnostics Initiative, and Cardiff University’s PET Imaging Scientific Committee. He is also a member of the Science Advisory Council for Wales.
Day 1 – Tuesday 13 March
18 19
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
Ian James Director, A4P Consulting
Ian is a Co-founder of A4P Consulting Ltd, established with colleagues from Pfizer’s EU Clinical Assay Group, to provide integrated solutions in outsourcing oversight, sample logistics and consulting services in clinical bioanalysis and diagnostic programs to pharma and SMEs.
In 1998 Ian joined Pfizer Global Research and Development as a Pharmacodynamic Assay Advisor and was responsible for biomarker selection, technology/assay development and outsourcing in support of early and late phase clinical programmes.
In 2007 he transitioned to a newly formed global companion diagnostics role continuing his prior work in HIV tropism diagnostic development for Maraviroc (CCR5 antagonist) and supporting additional HIV/HCV, oncology and anti-fungal programmes alongside various technology and near-patient platform development programmes.
Dr Nick Thomas Principal Scientist in Cell Technologies, GE Healthcare
Dr Thomas has a BSc in Biochemistry from the University of Glasgow and a PhD from the University of Wales College of Medicine. In a 28-year career with Amersham International, Amersham Pharmacia Biotech, Nycomed Amersham, Amersham, and GE Healthcare, he has held a number of positions in Operations, Marketing and Research and Development. He is the Inventor or Co-inventor of over 60 patents covering a wide range of technologies including microfabrication, and cellular imaging. Dr Thomas has worked on the development of cellular analysis instrumentation, software and reagents for 10 years.
Rowan Gardner BioLauncher
Rowan previously worked at Oxford Molecular Group and opened the company’s US operations. She also participated in the LSE main board listing as the company became the second best performing share. Rowan co-founded Synomics with recognised experts from the CERN computing lab and the European Bioinformatics Institute.
Rowan has worked with numerous start ups, several international companies and the NHS to find mechanisms to source investment. In 2007, she helped launch the Astia foundation’s investor readiness program in the UK and assisted with raising £5.3m of capital to develop a service level architecture for life science data integration. Rowan also chairs the Life Science Advisory Board in Europe.
Dr Berwyn Clarke Board Director and Chief Scientific Officer, Lab21
Dr Berwyn Clarke was Founder and CEO of Oneida TheraDiagnostics Ltd. Dr Clarke was Head of the Hepatitis C virus therapeutic area at GlaxoWellcome between 1990 and 2000 and previously worked with Wellcome Biotechnology and the Wellcome Foundation.
Dr Clarke moved into the molecular diagnostic industry with Virco UK and became Vice President for Research at Visible Genetics Inc – a pioneering company in the use of molecular diagnostics for viral and cancer disease management.
Dr Clarke co-founded Lab21 in April 2005 where he is currently a Board Director and Chief Scientific Officer. Lab21 is a leading provider of companion diagnostic services in Europe and a major global manufacturer of immunodiagnostic and molecular assays including tests for syphilis and malaria.
David Ford Director of eHealth Industries Innovation Centre (ehi2)
In addition to David’s role as Director of ehi2, he is University Director of Health Informatics Research Laboratories - a collaboration between the College of Medicine, Swansea University and NHS Wales Informatics Service. The laboratories provide state-of-the-art facilities to design, prototype, test and evaluate innovative new information technologies for use in improving healthcare. David is joint lead of the Health Information Research Unit for Wales (HIRU).
David is a Fellow of the Royal Society for the Encouragement of the Arts, Manufactures and Commerce (FRSA) and a Director of MediWales, a membership organisation representing the medical technology sector of Wales. He has received research grants and consultancy contracts valuing over £20m.
Dr Steven Conlan Head of the Reproductive Biology Group and Reader in Cell and Molecular Biology at the Institute of Life Science, Swansea University
Dr Steve Conlan’s research interests are reproductive biology using cell, molecular, and nanobiology approaches to investigate the underlying causes of, and ranges of, conditions including endometrial cancer.
Steve is Director of the Centre for NanoHealth (CNH), a £22million R&D facility. A joint initiative between the Colleges of Medicine, Engineering and Science at Swansea University, CNH offers a fully integrated nanotechnology and biomedical R&D environment within a purpose-built, open access facility.
A graduate of Swansea University, Steve completed his PhD at the University of London and undertook postdoctoral research at the John Innes Centre in Norwich and the IMBB-FORTH in Crete, Greece.
MC – Sue Heatherington Heatherington & Co
Sue’s passion for improving health outcomes through collaboration stems from her many years of experience as an NHS CEO in England and Wales. Recognising a drive for improvement expressed by highly motivated and talented professionals, she sought to create the environment where collaborative leadership could flourish and real, whole system change could occur, even against a backdrop of financial challenge. This included wider partnership work with universities, social care and others.
Sue recently launched Heatherington & Co based north of Swansea, together with a talented group of colleagues who thrive on wanting to make a difference. Sue’s clients range across healthcare, life sciences and academia, including SMEs, where she creates space for conversations that matter.
MorningMichael Hunt BSc ACA CEO, ReNeuron Group
Prior to his appointment as CEO of ReNeuron Group plc in July 2005, Michael spent six years at Biocompatibles International plc (sold to BTG plc) where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. He sits on the BioIndustry Association’s Cell Therapy and Regenerative Medicine Advisory Committee and its Finance and Tax Advisory Committee. Michael is a Senior Industry Group member of the UK Government’s Office for Life Sciences and a member of the UK Technology Strategy Board’s RegenMed Advisory Group. He read economics at University College London and qualified as a chartered accountant with Ernst & Young in London.
Professor Jonathan Bisson Clinical Director, National Institute for Social Care and Health Research (NISHCR), Academic Health Science Collaboration (AHSC)
In addition to Professor Jonathan Bisson’s role as Clinical Director, NISCHR AHSC, he is a Director of Research and Development for Cardiff University’s School of Medicine and Cardiff and Vale University Health Board. Jonathan is a Consultant Psychiatrist who developed an interest in traumatic stress during his time in the British Army. He has conducted various studies including two widely cited trials of early psychological interventions following traumatic events and three Cochrane systematic reviews in the traumatic stress field.
He was Co-chair of the UK’s PTSD NICE Guideline Development Group and is Director of the All Wales Veterans’ Health and Wellbeing Service.
Dr Trevor Howe Head of Structural Biology and Biophysics, Janssen Research & Development, a Johnson & Johnson Company
Dr Trevor Howe and his group are focused on using structural, biophysical and computational methods for drug discovery and optimisation. Increasingly, the focus encompasses pathway/target identification and validation in translational systems which require the use, interpretation and understanding of highly heterogeneous data types.
Prior to joining Janssen in 2003, Trevor headed the Computational Chemistry Council for Novartis. He established Lilly’s computational chemistry department in the UK and was a visiting researcher at the University of Oxford. He obtained his PhD at the University of East Anglia. He is currently a visiting Fellow at the Universities of Bristol and Cardiff and is a member of the Scientific Advisory Board for the EPSRC.
AfternoonMike Thompson Managing Director, Biomet UK Healthcare Ltd
Mike Thompson has worked for Biomet - a global supplier of orthopaedic devices – for 2 years. Mike has over twenty years experience of sales and marketing in the global orthopaedic industry. He has worked for DePuy and Johnson & Johnson in a number of commercial roles, including Vice President of International Marketing, Worldwide Vice President of Marketing & Product Development, and President of Europe for DePuy International Ltd. Mike’s aim is to expand Biomet’s product and service offering to meet the needs of an increasingly challenging environment.
Day 2 – Wednesday 14 March20 21
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
Kenneth Powell Executive Chairman, Q Chip
Kenneth is Executive Chairman of Q Chip – a Cardiff based company which develops novel delayed release formulations of drugs. Kenneth was the Founder and CEO of Arrow Therapeutics Ltd – a specialised antiviral drug discovery company acquired by Astra-Zeneca PLC for $150 million in February 2007. Kenneth is Professor of Cell Biology and Virology and Deputy Director of the Wolfson Institute for Biomedical Research at UCL. He is also Head of Biology for the Wellcome Foundation.
Ken has been involved in setting up and developing UK biotechnology companies across multiple therapeutic areas and utilising different business models. His companies have been involved in licensing deals with Pfizer, Novartis, Astra-Zeneca and GSK.
Dr Pete Corish British Biocell International
Dr Pete Corish is Head of Business Development for BBI Group and leads the internal technology acquisition group, BBInnovations. Pete is responsible for the sourcing, development and commercialisation of new technologies to maintain BBI’s position as the leading lateral flow assay developer and the acquisition of reagent-based products that underpin future IVD markets. This includes the extension of BBI’s core gold nanoparticle reagents into life science and novel biosensing applications.
As part of Alere (formerly Inverness Medical Innovations) he also maintains a watching brief on the rapid developments in molecular and immunoassay point-of-care and the increasing role of personalised medicine and companion diagnostics in 21st century healthcare provision.
Facilitated Finance DiscussionDominic Griffiths Senior Life Science Director, Fusion IP
Dominic is responsible for identifying and establishing new businesses arising from the Life Sciences portfolio of Fusion IP - a university IP commercialisation company that turns world class research into business.
Dominic has established four spinouts that have secured over £5m in early stage funding since incorporation and currently holds directorships of Fusion IP Cardiff, Abcellute, Asalus Medical Instruments and Progenteq. Before joining Fusion IP, Dominic was responsible for business development activities of an AIM-listed drug delivery company, Phoqus Pharmaceuticals. Dominic holds a PhD in biochemistry.
Dr Melanie Goward Investment Executive, Finance Wales
Melanie is an investment executive working on early stage investments at fund management company Finance Wales. Finance Wales makes commercial investments into small and medium-sized businesses throughout Wales and specialises in early-stage technology, development capital and succession deals.
Melanie previously worked as an Investment Director with the National Endowment for Science Technology and the Arts (NESTA) and at Lloyds TSB Corporate working with technology companies at all growth stages. Melanie holds a Ph.D. and B.A. (Hons) from the University of Cambridge.
Brenig Preest Investment Director, Excalibur Group Holdings
Brenig is an Investment Director at Excalibur in London and Cardiff, specialising in life science investments. For over 10 years Brenig has invested in a wide range of successful growth and venture businesses. Prior to this, he worked at GE Healthcare, before becoming a corporate finance advisor. As an investor and advisor Brenig has been involved in £0.5bn of transactions. Brenig studied pharmacology at Cardiff University and financial strategy at Oxford University. He is also a qualified chartered accountant.
UKTI Workshop HostAnne Avidon USA Sector Lead for Healthcare and Medical Devices
Anne Avidon is the USA Sector Lead for Healthcare and Medical Devices for UK Trade & Investment. Anne guides UK businesses in commercialising their medical devices and technologies in the US market. Anne has a Masters Degree from the University of Westminster, and is an active member of the Massachusetts Medical Device Industry Association (MassMEDIC), the Medical Development Group (MDG), the New England Health Information Management Systems Society (NEHIMSS) and the Massachusetts Technology Leadership Council (MTLC).
22
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
The Welsh Government is a democratically elected body. It has devolved powers and is responsible for developing and delivering policies in Wales covering many aspects of life including economic development, education, skills and technology and innovation. Life science is a priority sector and a dedicated team is in place to support the growth and business development of this sector in Wales. Activities include trade, skills development, property needs, routes to market and Foreign Direct Investment (FDI).
Attending: Jennifer Clark Innovation Promotion Manager Stella Asprou Innovation Stakeholder Engagement Executive
We are part of the Welsh Government’s department for Business, Enterprise, Technology and Science (BETS). Our support is aimed specifically at technology-based businesses in Wales in 9 key sectors including life sciences. We provide an integrated package of funding and support for all aspects of your business, from helping you develop new products and manage intellectual property assets, through design issues and manufacturing, to full commercialisation of your new products, services, processes and technologies. Our support is available at every step of the innovation process.
Our Regional Centre Service can provide you with the opportunity to speak to someone face to face who’ll get to know what makes your business tick, and give you valuable information and guidance for free. Business advice and support on your doorstep.
AbD Serotec prides itself on its commitment to providing research & industry customers the highest quality products & services. Our production facility in Oxford, UK, is certified to the ISO 9001 and ISO 13485 standards. We can offer:
• Over 15,000 antibodies and reagents• Large & small scale custom antibody production & conjugation services.
Our reputation has been earned through long-term collaborations and partnerships with key life science and diagnostic companies around the world.
Acerchem
Attending:Jeff Jiang General ManagerThomas Walsh Business Development Manager
Acerchem considers itself to be one of the global market leaders in the market sectors it operates in. We put our customers first in a constantly evolving and growing market place. We continually promote best practice in areas of cost, quality and customer service with both existing and new customers. The Business, since January 2011, now has an office in the UK, located at Swansea University operating out of the Institute of Life Science. This initiative unites Research and Development programs we currently support in China along with anticipated plans with the University.
Adelphi Healthcare Packaging
Attending:Gavin Crauford Taylor Sales Director
Adelphi Healthcare Packaging specialises in the supply of primary packaging to both the pharmaceutical and biotechnology industries and holds a comprehensive range of glass, plastic and aluminium containers, precision dispensing systems, and various closures including stoppers, crimp seals and screw caps.
Adelphi stocks a number of specialist vials and stoppers that are particularly suited to new product development and that provide a highly inert product contact surface. Our particular speciality is helping companies in the very early stages of development to ensure that primary packaging choices are the most appropriate, both commercially and technically for their products.
Exhibitor Profiles
Attending: Cari-Anne Quinn Senior Business Development Manager
14th MarchRos Duggan Customer Services OfficerKaty Pritchard Customer Services OfficerIestyn Thomas Environmental Management AdvisorJulian Rowe Business AdvisorAngharad Brown Business Advisor
BioDundee
Attending:Dr Adrian Mason BioDundee Coordinator
BioDundee was created in 1998 to help Dundee forge its reputation as a centre of excellence in life sciences and has continued to enable the sector to retain its competitive edge in a challenging global environment. Outside of Oxford and Cambridge, Dundee is home to one of the most significant life science communities in the UK. With world-class companies, universities and research institutions all within a three mile radius, the area offers a wide range of expertise from drug discovery, through medical devices and diagnostics to ag-biotech and environmental biotechnology. BioDundee brings together the local life science community as well as promoting its strength to external audiences around the world. BioDundee provides training and networking events, as well as offering marketing support through use of the internationally recognised brand at exhibitions, through newsletters and at the BioDundee International Conference held each summer - this year to be held on 30th & 31st May.
City Development Department Dundee City Council3 City Square Dundee Scotland DD1 3BATel: +44 (0) 1382 434913www.biodundee.co.uk Email: [email protected]
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
BBSRC - Biotechnology and Biological Sciences Research Council
Biotec Services International
Cardiff Medicentre
Attending: James Phillips Business Interface Manager
Polaris HouseNorth Star AvenueSwindonWiltshire SN21UHTel: 01793 413200www.bbsrc.ac.uk Email: [email protected]
BBSRC is one of 7 Research Councils that make up Research Councils UK (RCUK). With a variety of funding schemes it supports academic research in biology and biotechnology, which is not only of an excellent quality, but also achieves impacts to benefit society and industry in the UK. Of particular relevance is the Bioprocessing Research Industry Club (BRIC), a scheme co-funded by EPSRC and industry, which funds research of relevance to the bioprocessing sector.
Attending:Paul Viggers Business Development ManagerSamantha James Business Development Associate
Biotec has established itself as an international, trusted partner delivering GMP temperature controlled pharmaceutical services. Our core services include QP & GMP Consultancy, Clinical Supplies Services, GMP Temperature Controlled Storage, Global Logistics, Advanced Therapeutic Medicinal Products and Commercial Services. Providing such specialist services to large industry sectors requires flexibility, expert knowledge and dedicated personnel; three areas in which Biotec has built an esteemed reputation. Trust Biotec to be your international partner in clinical trials.
Cardiff Medicentre is a dedicated medical, healthcare, and life sciences business incubator located on the University Hospital of Wales campus. It offers high quality office and laboratory accommodation comprising 32 units ranging from 284 sq ft to 1,045 sq ft. Low-cost desk leasing is also available. Cardiff Medicentre offers specialist business incubation programmes and works closely with the Welsh Government’s Life Sciences Sector Team to ensure tenants have access to government business support services.
Cardiff University School of Biosciences
Attending:Professor Adrian Harwood (Head of Innovation, Partnership & Engagement) Miss Emma Dalton (Biosciences Communication Officer)
Cardiff School of BiosciencesBiomedical Sciences BuildingMuseum AvenueCardiff CF10 3AXTel: 02920874238 or 02920879358www.cardiff.ac.uk/biosiEmail: [email protected] or [email protected]
The Cardiff University School of Biosciences possesses an international reputation for its biological research. In the authoritative 2010 World Rankings compiled by Shanghai Jiao Tong University, the School features in the top 100 worldwide and in the top 10 in the UK. We have strengths across the spectrum of biological research, obtaining more than £21M of research awards in the last 2 years including research councils, charities and industry. We promote innovation through interdisciplinary research, and host the Cardiff Cancer Research UK Centre, the Arthritis Research UK Biomechanics and Bioengineering Centre, and are a major partner in three new collaborative translational research institutes focusing on cancer stem cell biology, mental health and sustainable environments. In addition, our researchers have an impressive record of translating and commercialising their research and have a highly developed network of industrial partners drawn from the UK, Europe and internationally.
CIIC Shanghai Bio-Medical Development Corporation
Attending:Ms Min Yuan Project DirectorDr Dazhen Wen General ManagerMr Dez M Stowe Overseas Manager
CIICBM is recognised internationally as a leading Chinese biomedical industry services supplier and a niche player in the biomedical technology market in China. Our core services include: Biomedical Training (GLP, GCP, GMP etc.), Clinical Consumables Supply, and Pre-Clinical Technology Commercialization. CIICBM is committed to building ”international two-way channels” to promote Chinese-British biomedical industry collaborations.
eHealth Industries Innovation Centre (ehi²)
Attending:Julie Kennedy Business Development ManagerJames Davies Business Development ManagerEmma Hughes Network CoordinatorStephanie Lee Marketing & Network Manager
Second Floor, Institute of Life Science (Building 2)Swansea University, Singleton ParkSwanseaWales SA2 8PPTel: +44 (0) 1792 606838www.ehi2.swansea.ac.uk/en Email: [email protected]
ehi² Centre works with companies in creating new, innovative ehealth products and services with global market potential. It provides businesses with opportunities to test, adapt, improve and evaluate ehealth products and services in a safe and reliable environment to maximise their competitive advantage. It advises and assists companies and where needed, facilitates access to clinicians, academic experts, NHS organisations, and national NHS IT and ICT programmes.
Attending:Alun Bevan Applications EngineerChris Vince Technical and Applications Manager
Ensinger Precision Engineering is at the forefront of precision machining technology in engineering plastics. 2, 3, 4 and 5-axis CNC turning, milling and routing capacity is available as well as solutions for finishing, polishing, part marking, ultrasonic cleaning/packaging and assembly/kitting. The company are highly focussed on application engineering in the life science sector and work closely with customers on a technical level assisting in developing applications, specifying materials and optimising parts for manufacture.
With engineering support spread across the country, Esco GB Ltd aims to provide our clients with the best quality, best supported, most energy efficient and most affordable range of clean air and containment equipment available in the marketplace today. Our client base covers a multitude of industries including: universities, clean manufacturing plants, hospitals, medical research institutions and pharmaceutical companies.
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
Gael
GE Healthcare Life Sciences
GX Group
Attending: Lorna Elmslie Marketing Manager Healthcare & Life Sciences Deborah Scott Business Development Manager Healthcare & Life Sciences
Gael Ltd is a software solutions company that helps organisations manage governance, compliance and risk. Working with clients in the life sciences, aviation, healthcare, manufacturing and services sectors, Gael helps these companies demonstrate compliance to internationally recognised standards with their compliance management software solution, Q-Pulse. Over 2500 organisations globally use it on a daily basis to successfully manage their compliance requirements.
Attending:Dan Arkwell Custom Products and Contract Manufacturing Account Manager, Northern Europe Warwick May Custom Products and Contract Manufacturing Sales Manager, UK & Ireland
GE Healthcare Life Sciences provides tools for drug discovery, biopharmaceutical manufacturing and cellular technologies, so research scientists worldwide can be more productive, effective and creative. Our vision is to be the start-to-finish bioprocessing solution provider, the partner of choice in cell and protein research and the leader in life sciences services. Building on our broad expertise across life sciences, we are firmly committed to help researchers understand life at a molecular level and develop solutions that can prevent, diagnose, treat, and cure disease.
Attending:Claire Banks Business Development ManagerMark Helmich Managing Director
The MayfieldUskMonmouthshire NP15 1SYUKTel: +44 (0) 1291 673437www.gxgroup.com/designEmail: [email protected]
Our talented and friendly in-house team is fascinated by the challenges presented by imaginative clients and offers a complete skill set for product development. This includes electronic hardware and software design, industrial and mechanical engineering plus specialist areas such as optronics and microfluidics. We combine these capabilities with creativity, experience and absolute problem solving intelligence to deliver solutions that are innovative, commercial and practical. We make it possible.
HealthTech and Medicines KTN
Attending:Sue Dunkerton Co-Director, HealthTech and Medicines KTNDr Daniel Smith Collaboration Manager, HealthTech and Medicines KTNNarpal Sihra Senior Marketing Manager, HealthTech and Medicines KTN
HealthTech and Medicines KTNGranta ParkGreat AbingtonCambridge CB21 6ALTel: +44(0)7584 214705 or +44(0)7766 051 340www.innovateuk.org/healthktnEmail: [email protected]
The HealthTech and Medicines Knowledge Transfer Network (KTN) supports business innovation through partnerships, funding and knowledge transfer:l Connecting partners: bringing together and facilitating collaborations with
a common goal l Access to funding: identify and influence new and existing sources of
fundingl Knowledge transfer: opening doors to wider networks of people,
organisationsThe KTN is dedicated to the advancement of knowledge transfer of technology into UK-based businesses and innovation within the key application areas of medicines, health technologies, regenerative medicine, stratified medicine and assisted living technologies (medical devices and diagnostics, biopharmaceutical bioprocessing), addressing needs across SMEs to large multinationals.Membership of the KTN provides access to:l Potential practitioner network into industry and industry friendly academial Technology Strategy Board, National and EU funding competitionsl Impartial advice and access to the full KTN teaml Putting you in touch with the right partners for forming collaborationsl Networking opportunities/events
Institute of Life Science, Swansea University
Attending:Sian Newman Head of CommunicationsEmma Turner Marketing and Projects CoordinatorMike Day Commercial ManagerKevin Fernquest Account Manager
College of Medicine Swansea University Singleton ParkSwansea SA2 8PP WalesTel: 01792 602697www.swan.ac.uk/ils/home Email: [email protected]
Swansea University is proud to be the Gold Sponsor for BioWales 2012. It is home to a thriving cluster of innovative life science and healthcare ventures centred around the Institute of Life Science (ILS). ILS provides access to exceptional resources for clients including clinical research and imaging facilities, a UK centre for mass spectrometry, commercial laboratory space, business suites, hot-desk facilities and access to partner initiatives such as the Centre for NanoHealth and APT Bioscience.
Johnson & Johnson – Ortho Clinical Diagnostics
Attending: Mark Lloyd Davies Senior Director Government Affairs & Policy, UK and Ireland
We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. Our family of companies comprises: l The world’s sixth-largest consumer health company l The world’s largest and most diverse medical devices and diagnostics
companyl The world’s fifth-largest biologics company l And the world’s eighth-largest pharmaceuticals company We have more than 250 operating companies in 60 countries employing approximately 118,000 people. Our worldwide headquarters is in New Brunswick, New Jersey, USA.
KnowledgeTransferNetwork
HealthTechand Medicines
28 29
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
Based in Ringmer, Sussex, Labtech International Limited is a distributor of life science instrumentation in the United Kingdom and France. Representing many major manufacturers on an exclusive basis, Labtech International Limited provides exceptional technical, applications and service support together with personal service that ensures a high level of customer satisfaction. Committed to continuous development of products and services, Labtech International Limited endeavours to provide significant added value for its customers at all levels.
Lion Laboratories
Attending:Charles Squire UK Sales ManagerNigel Wood Export Sales Manager
Lion Laboratories (Lion) is one of the world’s leading manufacturers of breath alcohol testing equipment, supplying high quality and innovative products into various market sectors, including law enforcement, medical, industrial/commercial, health and safety, and education. Lion supplies much of the equipment used by the UK police and the NHS, and exports worldwide for sales into the above sectors through a network of local distributors. The use of lion alcolmeters® has grown significantly over the years, and the range includes hand-held screeners and static/mobile units for evidential purposes. Lion’s service department prides itself on its efficient and speedy product turnaround.
Medilink UK
Attending:Kevin Kiely Managing DirectorJulia Fu Events & Membership Co-ordinator
Confronting the day-to-day issues that face businesses, Medilink UK helps companies from concept through to commercialisation and nurtures collaborations between academics, clinicians and industry. With a team of experts, Medilink UK can provide bespoke market research for companies diversifying into the sector, or investing in research and development. On an international platform, Medilink UK supports global companies investing in the UK market as well as promoting the export of products and services to the US, Middle East and Asia.
NHS Wales Informatics Service (NWIS) is a national organisation providing the information and technology services used by NHS Wales to support high quality patient care. Our work covers the development of new national products and the delivery of operational technology and information services. All products and services are developed in collaboration with health boards and health professionals in NHS Wales, to meet the needs of NHS Wales now and in the future.
National Institute for Social Care and Health Research (NISCHR)
Attending: Bev Luchmun Commercial Trials, NHS Innovation & IP Lead
Department for Public Health and Health Professions Welsh Government, Cathays ParkCathays, Cardiff CF10 3NQWalesTel: 029 20825252www.nischr.org.uk Email: [email protected]
The National Institute for Social Care and Health Research (NISCHR) is the Welsh Government body that develops strategy and policy for research in the NHS and social care in Wales. NISCHR fund two key elements of infrastructure to assist in the delivery of research and development. The NISCHR Academic Health Sciences Collaboration (AHSC) facilitates collaboration between industry, HEIs and the NHS. The NISCHR Clinical Research Centre (NISCHR CRC) provides an expert research workforce to support and develop research activity within health and social care.
Pall is the world leader in the design, production, and supply of membranes, filtration devices, and separation systems. We supply products to nearly every industry in the world, including the most sophisticated and demanding applications in drug discovery, diagnostics, healthcare, and industrial fluid processing. We are a global, multi-site manufacturer with an impressive portfolio of products, quality systems, and experience to meet demanding material requirements.
Pall offers the widest selection of membranes with the broadest range of performance characteristics, making it easy for you to find the best membrane fit for your product. Pall combines its extensive membrane manufacturing capabilities with advanced device engineering and design expertise to create unique and reliable solutions to your specific application needs. Our adherence to internationally recognised quality and six sigma principles assure consistent lot-to-lot performance and regulatory compliance.
Pall’s OEM division at BioWales specialises in membranes for diagnostics and healthcare devices.
Patent Seekers
Attending: Timothy Parry Business and Finance Director
We are experts in patent, design and research journal searching, supporting patent attorneys, companies and R & D departments worldwide. We cover all areas of search and analysis to assess prior art for new patent/design applications, produce patent/design landscapes, provide potential prior art for revocation proceedings, or to determine the risks of infringement. Our comprehensive range of databases cover more than 75 countries worldwide.
30 31
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
PDR (The National Centre for Product Design and Development Research)
PDR is a world renowned design consultancy and research centre offering comprehensive product development support. PDR has considerable experience in medical device development in all classifications from simple disability devices and rehabilitation equipment through to complex diagnostic tools and drug delivery systems. Device development at PDR is undertaken through a proven design methodology that employs the latest design and manufacturing analysis tools and technologies to produce robust, compliant and commercially successful solutions.
Penn Pharma
Attending: Agata Jankowska Business Development & Marketing AssociateRob Jones Business Development DirectorJohn Roberts Commercial Director
Penn’s services support a fast and effective route from drug discovery through clinical trials to market. Penn’s services, developed over its 30 year trading history, are individually excellent and compelling in combination and include pharmaceutical development, manufacturing of clinical and commercial supplies and analytical test and release service. Penn operates under quality systems proven through audit and compliance with EU GMP. Penn is licensed by the MHRA for manufacturing, importation and distribution of medical products and we supply products to USA under the approval of the FDA. Penn has specialised facilities for handling potent compounds requiring contained resources and we are is licensed by the UK Home Office for the production of controlled drugs.
Reed Scientific
Attending:Dawod Kaaba Senior Executive ConsultantSean Martin Scientific Interims Specialist
Reed Scientific is a leading specialist recruiter dedicated to the scientific and clinical sectors. We specialise in sourcing talented individuals for roles across industry sectors, including: Bioanalytical, Biotechnology, Chemical, Contract Testing, Diagnostic, Environmental, Food, Forensic, Health and Safety, Life Sciences, Manufacturing, Medical Device, Nutrachemical, Petrochemical and Pharmaceutical. We utilise our UK-wide office network and global advertising reach to meet our clients’ requirements in Wales and around the globe.
Seralab
Attending:Jenny Murray Managing DirectorRosie Davies Business Development Manager
Unit 44, Bolney Grange Business Park Haywards HeathWest Sussex RH17 5PBUKTel: 01444 250010www.seralab.co.uk Email: [email protected]
Seralab is a leading supplier of control matrices and disease state material from both human and animal models. The company offers the most complete range of human and animal-based bio products in Europe. Seralab supplies serum, plasma, whole blood, tissues, microsomes, S9 fractions and fluids from the human model and an extensive range of animal species. Other products include Cell Culture sera and reagents including FBS, Cell Specific media selected growth factors and Stem Cell reagents.
Simbec
Attending:Lydia Vitolo International Account Manager
Trials conducted range from Phase I studies in healthy subjects through to Phase II trials in patients, with full bioanalytical back-up and related services. Simbec specializes in early drug development, particularly first-into-human, and has 35 years experience in clinical & bioanalytical research. Simbec’s investigator centre, central laboratory and bioanalytical unit are all located on one site. Supplementary Accredited for Phase 1 research.
Source BioScience LifeSciences
Attending:Andrew Jones BSc MA Sales Specialist, Life Sciences
Source BioScience LifeSciences are European leaders in DNA sequencing, genomic services, bioinformatic analyses and offer a comprehensive portfolio of genomic reagents and antibodies.
Source BioScience LifeSciences offer a unique Sanger sequencing service; our local facilities in London, Cambridge, Oxford, Nottingham, Dublin and Berlin combined with our Overnight Service mean we have the flexibility to meet your entire DNA sequencing requirements.
Our contract research services feature a broad range of microarray, genotyping and gene expression applications on Affymetrix, Agilent, and NimbleGen Fluidigm platforms.
Swansea Metropolitan University – Design for Successful Ageing (DSA)
Attending:Dr Huw Millward Senior Research Officer, Cardiff Metropolitan UniversityProfessor Peter McCarthy University of GlamorganDr Drew I Heusch Senior Lecturer, University of Glamorgan
Mount PleasantSwansea SA1 6ED WalesTel: 07977 504 847www.dsawales.com Email: [email protected]
Design for Successful Ageing (DSA) is a Knowledge Exchange Partnership (KEP) that aims to address age and occupational related assisted living problems by identifying the need for early design interventions to reduce the effects of poor ergonomics on the population as it ages. The scope of this KEP is multifaceted due to the nature of the requirements of the target population. This can be in relation to health, hospital/home care, well-being, human rights and personal dignity. The proposition, summarised by four over arching themes, is that effective and well implemented ergonomic product design enhanced and informed by high level medical research, can have a positive effect and lead to successful ageing.
The identified themes are:l Design for Assisted Livingl Psychology of Design Interventionsl Design for Clinical Engineeringl Ergonomic Evaluation
Dr Ross Head Lecturer, Swansea Metropolitan UniversityIan Williams Product Designer, Swansea Metropolitan UniversityChristopher Thomas Industrial Design Lecturer, Swansea Metropolitan University
32 33
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
University of Glamorgan
Attending:Louise MacCormac Knowledge Transfer Officer (Partnerships)
University of Glamorgan Commercial Services Pontypridd CF37 1DLWalesTel: +44 (0)1443 482776 or 07922891373www.glam.ac.uk Email: [email protected]
We are committed to working with the biosciences sector across Wales. The Advanced Analytical Science Research team within the Sustainable Environment Research Centre (SERC) hosts one of the most modern analytical laboratories in the UK. The Centre for Electronic Product Engineering (CEPE) provides expertise in embedded microelectronics and communication technologies. We are a team of experienced knowledge transfer specialists with an excellent track record of understanding, meeting and surpassing client needs.
Welsh Opto-Electronics Forum
Attending:Dave Rimmer MD DREM Ventures Ltd / Welsh Opto-Electronics Forum Deputy ChairSusan Sheridan Projects Manager Welsh Opto-Electronics Forum
OpTIC TechniumSt Asaph Business ParkLL17 0JDTel: 07785 242455 or 07807 263184www.wof.org.uk Email: [email protected] or [email protected]
WOF are an independent body which aims to bring people together thereby facilitating the process of research, technology transfer, and generation of business opportunities. Our primary focus is the manufacture and development of materials, components, instrumentation, and systems based on, or enabled by Optics; Optoelectronics; Photonics. These technologies play a major role in most of our key industries – including Life Sciences. We are pleased to represent our members involved here in medical devices and bio-photonics.
Ziath
Attending:Neil Benn Managing DirectorKay Newell Sales & Marketing Director
Ziath specialises in the development and manufacture of 2D barcode readers. Our scanners are compatible with all the major manufacturers of 2D barcoded tubes and can offer bespoke solutions to suit your requirements. We design and build our scanners, write our own software and offer expert support for all your barcoding needs.
34 Catering Point
Caterin
g Po
int
20
21
22 23 24
25 26 27
28 29 30
31 32
34 35
33
36
37
38
Catering Point
Cat
erin
g P
oin
t
1
10
11
1312
14 15
16 17
2
18 19
Exhibition Hall 1
1 Medilink UK
2 PDR
3 Gael
4 HealthTech and Medicines KTN
5 Seralab
6 Cardiff Medicentre
7 GX Group
8 Swansea University
9 NHS Wales Informatics Service
10 Labtech International
11 Acerchem
12 Swansea Metropolitan University – Design for Successful Ageing (DSA)
13 CIIC Shanghai Bio-Medical Development Corporation
14 AbD Serotec
15 Esco GB
16 Penn Pharma
17 Johnson & Johnson – Ortho Clinical Diagnostics
18 eHealth Industries Innovation Centre (ehi²)
19 Biotec Services International
BioWalesWa l e s , L i f e S c i e n c e a n d t h e Wo r l d
3 4
5
7
9
6
8
Exhibition Hall 2
20 National Institute for Social Care and Health Research (NISCHR)
21 GE Healthcare Life Sciences
22 Patent Seekers
23 Welsh Opto-Electronics Forum
24 Welsh Government – Regional Centre Service
25 Source BioScience LifeSciences
26 Welsh Government – Innovation Team
27 Adelphi Healthcare Packaging
28 Reed Scientific
29 Pall Life Sciences
30 Ensinger Precision Engineering
31 Simbec
32 Ziath
33 BioDundee
34 Lion Laboratories
35 BBSRC – Biotechnology and Biological Sciences Research Council
36 Cardiff University School of Biosciences
37 University of Glamorgan
38 Welsh Government – Life Sciences Sector Team
Exhibitor List 2012
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
The MediWales Innovation Awards 2011 Innovate, Collaborate, Celebrate
The Innovation Award was won by ConvaTec Ltd, for their AQUACEL® SURGICAL dressings designed for use over joints following knee or hip replacement surgery. Extensible and absorbent, they provide surgeons with a high-performance, one piece dressing that addresses the clinical and economic challenges of skin blistering, infection and delayed discharge following joint repair. This award was sponsored by SMTL.
The Start-Up Award was picked up by spinout company Microvisk Technologies, which is developing the world’s first medical diagnostic strip based on a Micro-Electro-Mechanical System (MEMS) used in devices such as the iPhone. This patented nanotechnology detects the subtle changes in blood viscosity and monitors blood clotting in warfarin patients. The company has worked closely with NHS North West and will commercialise in 2012. This award was sponsored by the Health Protection Agency.
For the second year running Chromogenex won the Export Achievement Award. A leader in the development and manufacture of laser systems for the cosmetic and medical markets, their strategy focuses on the high growth markets of Brazil, the Far East, India, South Africa, as well as Europe and North America. Despite difficult economic times the company has had an average annual growth of 75% for three consecutive years. This award was sponsored by DTR Medical.
Biotec Services International won the Outstanding Growth Award. Based in Bridgend, they are a global provider of temperature controlled pharmaceutical services, specialising in import, qualified person certification, labelling, assembly, storage and worldwide distribution of clinical trials supplies. Turning over £7.3 million, they have seen 110% growth in the last year. Since winning the MediWales Award in December, Biotec has unveiled plans to double capacity thanks to an investment of £800,000 that will see staff numbers grow from 39 to 55 over the coming months. This award was sponsored by Teamworks Design and Marketing.
Kicking off at 6.30pm on 8th December, 250 of MediWales’ most valued members and stakeholders sipped champagne in front of the Christmas tree at Cardiff’s Hilton Hotel.
After an opening speech from the First Minister of Wales Rt Hon. Carwyn Jones AM, biotech
In partnership with Welsh Government’s National Institute for Social Care and Health Research (NISCHR), the MediWales Innovation Awards celebrate the remarkable innovations within both Welsh industry and NHS organisations.
entrepreneur Sir Chris Evans and the chief medical officer for Wales Dr Tony Jewell, among others, presented six prestigious awards to industry, and three to NHS departments.
Our biggest dinner yet, MediWales gives special thanks to its event
sponsors GE Healthcare, Geldards LLP, Abel & Imray, GX Group and Huntleigh whose support made the evening such a renowned success.
Accompanied by short films dedicated to each award winner, the following companies and NHS departments received awards:
A highly collaborative industry–NHS partnership was recognised this year with Flexicare Medical winning the Partnership with the NHS Award for the development of non-interchangeable connectors that stop drugs being given to patients by the wrong route. The Hall Lock is the only system with a full range of needles, syringes, manometers and tamper evident caps meeting the needs of the anaesthetic and pharmaceutical markets. This award was sponsored by eHealth Industries Innovation (ehi2) Centre.
The Industry Judges’ Award was won by Calon Cardio-Technology, a pre-revenue company specialising in the development of low-cost, minimally invasive blood pumps for the treatment of chronic and acute heart failure. The team of seven have developed a haemolysis-free pump currently in line for acute in vivo trials. In just four years, and despite recession, they have raised investment of £2.2million.
t
t
t
t
t
t
36 37
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
Plan
The Innovation within the NHS Award was won by Mr Richard Penketh, a Consultant Obstetrician and Gynaecologist at Cardiff
and Vale University Health Board. Richard’s project, enabled by a health
foundation grant and an equipment loan from Karl Storz, relocates the traditional procedure of cutting fibroids and polyps
under general anaesthetic to outpatients under local anaesthetic. The project has
received excellent feedback from patients and has made significant savings for the
Trust. The aim is for UK wide adoption. This award was sponsored by Wynne-
Jones, Lainé& James LLP.
The NHS Partnership with Industry Award went to Professor Judith Hall, a consultant anaesthetist at Cardiff and Vale University Health Board, for the collaborative development of the Hall Lock device with Flexicare Medical. Judith’s brain child, this new system of connectors is designed to stop drugs being given to patients by the wrong route. It is an important patient safety innovation and a cost-effective solution for a major problem in health. The development of this device is an excellent example of what can be rapidly achieved when academia, the NHS and industry work together. This award is sponsored by the National Institute of Social Care and Health Research (NISCHR).
The NHS Judges’ Award was received by Dr Kathryn Head, Clinical Lead
and Speech and Language Therapist at Cwm Taf Health Board. Kathryn’s
collaborative University of Glamorgan and Cwm Taf project is a bedside
dysphagia screening process aimed at improving patient safety. Dysphagia - difficulty in swallowing - affects up to
78% of stroke patients. The process has been successfully implemented by NHS
nurses. With further collaboration and funding Kathryn intends to roll it out
across Wales.
tt
t
38
ASTUTE is a £27m, 5 year project part funded by the EU’s European Regional Development Fund through the Welsh Government, which aims to boost the competitiveness of the Welsh economy through supporting manufacturers & their supply chains within the Wales Convergence Area, including the Valleys, West and Northwest Wales. The project provides Welsh industry with ready access to the unique combination of technical and business expertise, specialist equipment and resources available across 8 Welsh Universities, providing assistance with key industry challenges to facilitate industrial growth and long term sustainability. ASTUTE can help your business by providing specialist advice as well as technical assistance through collaborative R&D projects in adopting new technologies or improving your business processes. We have within our team a wide range of expertise of direct relevance to bioscience businesses in Wales, including:
Mae ASTUTE yn brosiect £27m, 5 mlynedd a gyllidir yn rhannol gan Gronfa Datblygu Rhanbarthol Ewrop yr Undeb Ewropeaidd drwy Lywodraeth Cymru, sy’n bwriadu rhoi hwb i ysfa’r economi Gymreig i gystadlu drwy gefnogi cynhyrchwyr a’u cadwynau cyflenwi o fewn Ardal Gydgyfeirio Cymru, yn cynnwys y Cymoedd, Gorllewin Cymru a Gogledd Orllewin Cymru. Mae’r prosiect yn rhoi mynediad hwylus i ddiwydiannau Cymru i’r cyfuniad unigryw o arbenigedd technegol, arbenigedd busnes ac offer ac adnoddau arbenigol sydd ar gael ar draws 8 o Brifysgolion Cymru ac yn helpu i fynd i’r afael â’u sialensiau allweddol i hwyluso twf diwydiannol a chynaliadwyedd tymor-hir. Gall ASTUTE helpu’ch busnes drwy ddarparu cyngor arbenigol yn ogystal â chymorth technegol ar ffurf prosiectau i gydweithio ar waith ymchwil a datblygu a fydd yn mabwysiadu technolegau newydd neu’n gwella prosesau’ch busnes. Mae’n tîm ni’n cynnwys amrywiaeth mawr o arbenigedd sy’n uniongyrchol berthnasol i fusnesau ym maes y biowyddorau yng Nghymru, gan gynnwys:
Uwch-Dechnolegau: Bioleg y Moleciwl, Cemeg Prosesau, Microweithgynhyrchu, Micro / nano-metroleg, Microreolyddion, Gwneud prif batrymau / offer, Prototeipio a Dyblygu
Dylunio ac Arloesi: Dylunio a gweithgynhyrchu’n ddigidol, Dylunio Dyfeisiau Meddygol, Dylunio Cynhyrchion a Phrosesau
Rheoli Gweithrediadau: Arferion Gweithgynhyrchu Da a Gweithgynhyrchu mewn Ystafelloedd Glân, Gweithgynhyrchu Tynn a Chynaliadwy, Logisteg Cadwyni Cyflenwi
I gael gwybod rhagor ynghylch sut y gallwn ni helpu’ch busnes yn y biowyddorau, cysylltwch â Jacqueline Marsh yn Swyddfa Prosiect ASTUTE yng Nghaerdydd
Ffôn: 02920 879611 E-bost: [email protected] Y We: www.astutewales.com Ystafell S2.39, Ysgol Peirianneg Caerdydd, Prifysgol Caerdydd, Adeilad y Frenhines, The Parade, Caerdydd CF24 3AA
For further information on how we can assist your bioscience business, please contact Jacqueline Marsh at the ASTUTE-Cardiff Project Office Tel: 02920 879611 Email: [email protected] Web: www.astutewales.com
Room S2.39, Cardiff School of Engineering, Cardiff University, Queens Buildings, The Parade, Cardiff CF24 3AA
Boost the Competitiveness of your Bioscience Business
Rhowch hwb i ysfa gystadleuol eich busnes biowyddorau
S P R I N G 2 0 1 2 l M E D I W A L E S R E V I E W
For further information, please contact:Dr Mark Bowman MBA Director of Innovation
Cardiff Medicentre is a dedicated medical, healthcare and life-sciences business incubator. It is located on the campus of the University Hospital of Wales and offers:� Easy-in, easy-out leases;� Units from 284 sq. ft. to 1045 sq. ft.;� Desk leasing facilities for pre-starts;� Access to academic expertise;� Manned reception;� 24 hour access, 365 days a year;� Secure parking;� Controlled security systems.
Cardiff Medicentre is the ideal place to locate your medical, healthcare or life-sciences company.
Well informed.Well read.News, developments and analysis from the magazine at the heart of the UK Lifescience Industry. Published by MedilinkUK and its partner organisations who are in daily contact with leading innovators, UK Lifescience Industry provides:
Production and distribution is supported by partners including:● iNets South West Biomedical ● MediWales● Medilink East Midlands● SEHTA● Medilink West Midlands● Medilink Yorkshire & Humber● ABHI● HealthTech and Medicines
KTN● One Nucleus● Scottish Enterprise● Medilink North West
Distributed to 38,000 named individuals with an estimated total readership of 100,000
W A L E S m e d i c a s p e c i a l
2
Precision Engineering Ltd
Total engineering solutions - from concept to reality
A solutions company, specialising in application engineering, part optimisation and